Deals Of The Week Road Tests Biopharma’s Options
The industry has pulled back on experimentation with option-to-license deals; results have been mediocre and biotechs, no longer as cash-strapped as they were in 2009, when option deals peaked, have other … options. Plus deals by Roche, Endo, Pfizer, GSK and others.
You may also be interested in...
Pfizer’s Centers for Therapeutic Innovation program has grown in less than three years to include 24 academic partners. First drug candidate to emerge from the research model is expected to enter the clinic this year, and Pfizer’s investment in CTI has grown.
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.